Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (A, C, and E) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best...

Descrición completa

Gardado en:

Detalles Bibliográficos
Autor Principal:	Kristoffer Staal Rohrberg (15009138) (author)
Outros autores:	Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Publicado:	2025
Subjects:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

_version_	1849927621926715392
author	Kristoffer Staal Rohrberg (15009138)
author2	Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
author_facet	Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
author_role	author
dc.creator.none.fl_str_mv	Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
dc.date.none.fl_str_mv	2025-11-26T07:40:32Z
dc.identifier.none.fl_str_mv	10.1158/2767-9764.30719289
dc.relation.none.fl_str_mv	https://figshare.com/articles/figure/Figure_1_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719289
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
dc.title.none.fl_str_mv	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
dc.type.none.fl_str_mv	Image Figure info:eu-repo/semantics/publishedVersion image
description	<p>Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (<b>A</b>, <b>C</b>, and <b>E</b>) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best overall response (<b>B</b>, <b>D</b>, and <b>F</b>). <b>A</b> and <b>B,</b> Cohort 1 (Q3W): NSCLC with sensitizing <i>EGFR</i> mutations and/or mutations targeted by third-generation TKIs (<i>n</i> = 22). <b>C</b> and <b>D,</b> Cohort 2 (2.2 mg/kg Q3W): NSCLC without activating <i>EGFR</i> mutations or <i>ALK</i> rearrangements (<i>n</i> = 55). <b>E</b> and <b>F,</b> Cohort 8 (3Q4W): NSCLC without activating <i>EGFR</i> mutations or <i>ALK</i> rearrangements (<i>n</i> = 26). NE, not evaluable; PD, progressive disease; PR, partial response.</p>
eu_rights_str_mv	openAccess
id	Manara_3f0083fb0262c3a7bee6bdb49bd87618
identifier_str_mv	10.1158/2767-9764.30719289
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30719289
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg (15009138)Juanita S. Lopez (22687839)Mohammed M. Milhem (15352499)Christian U. Blank (14850778)Irene Reijers (22687842)Fiona Thistlethwaite (22687845)Ruth Plummer (15028641)Sarina A. Piha-Paul (15294428)Pasi A. Jänne (14954872)Elaine Shum (14955138)Heather M. Shaw (22687848)Philip R. Debruyne (20432881)Cristopher Lao (22687851)Jean-Francois Baurain (15031089)Jennifer H. Choe (15052775)Eelke Gort (17740951)Yujie Zhao (22687854)Guy Jerusalem (15017648)Patrick Schöffski (15013461)Andrew William Chen (22687857)Eric A. Cohen (15017996)Walter C. Mankowski (22687860)Leonid Roshkovan (22687863)Sharyn I. Katz (22687866)Despina Kontos (15018005)Lauren K. Brady (22687869)Mohammed Qutaish (22687872)Patricia Garrido Castro (22687875)Nora Pencheva (22687878)Gaurav Bajaj (22687881)Yali Fu (22687884)Kristian Windfeld (22687887)Panagiota Reiter (22687890)Maria Jure-Kunkel (15117740)Brandon W. Higgs (15035279)Katayoun I. Amiri (22687893)Tahamtan Ahmadi (22687896)Ulf Forssmann (22687899)Suresh S. Ramalingam (14951413)Ignace Vergote (15027870)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsImmunologyAntibodies/immunoconjugatesLung CancerMelanomaOvarian CancerSarcomas<p>Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (<b>A</b>, <b>C</b>, and <b>E</b>) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best overall response (<b>B</b>, <b>D</b>, and <b>F</b>). <b>A</b> and <b>B,</b> Cohort 1 (Q3W): NSCLC with sensitizing <i>EGFR</i> mutations and/or mutations targeted by third-generation TKIs (<i>n</i> = 22). <b>C</b> and <b>D,</b> Cohort 2 (2.2 mg/kg Q3W): NSCLC without activating <i>EGFR</i> mutations or <i>ALK</i> rearrangements (<i>n</i> = 55). <b>E</b> and <b>F,</b> Cohort 8 (3Q4W): NSCLC without activating <i>EGFR</i> mutations or <i>ALK</i> rearrangements (<i>n</i> = 26). NE, not evaluable; PD, progressive disease; PR, partial response.</p>2025-11-26T07:40:32ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30719289https://figshare.com/articles/figure/Figure_1_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719289CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307192892025-11-26T07:40:32Z
spellingShingle	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Kristoffer Staal Rohrberg (15009138) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
status_str	publishedVersion
title	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_fullStr	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full_unstemmed	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_short	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_sort	Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
topic	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Títulos similares